HVC

Healthcare Value Capital Portfolio holdings

AUM $38.5M
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
1 Year Est. Return
+24.72%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$46.2M
AUM Growth
+$7.07M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
23
New
Increased
Reduced
Closed

Top Buys

1
+$1.63M
2
+$1.42M
3
+$1.37M
4
MDXG icon
MiMedx Group
MDXG
+$1.35M
5
ALKS icon
Alkermes
ALKS
+$1.11M

Top Sells

1
+$1.3M

Sector Composition

1 Healthcare 95.47%
2 Consumer Staples 3.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
1
Gilead Sciences
GILD
$180B
$5.17M 11.17%
75,000
GSK icon
2
GSK
GSK
$107B
$3.98M 8.61%
80,000
PFE icon
3
Pfizer
PFE
$151B
$3.92M 8.47%
100,000
ALKS icon
4
Alkermes
ALKS
$4.63B
$3.68M 7.95%
150,000
+50,000
BMY icon
5
Bristol-Myers Squibb
BMY
$120B
$3.34M 7.23%
50,000
+25,000
MRK icon
6
Merck
MRK
$286B
$3.11M 6.73%
40,000
+19,040
AZN icon
7
AstraZeneca
AZN
$295B
$3M 6.48%
50,000
+25,000
CLVS
8
DELISTED
Clovis Oncology, Inc.
CLVS
$2.9M 6.27%
500,000
+50,000
IRWD icon
9
Ironwood Pharmaceuticals
IRWD
$550M
$2.57M 5.57%
200,000
AMYT
10
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$2.43M 5.25%
200,000
+44,445
COLL icon
11
Collegium Pharmaceutical
COLL
$1.1B
$2.36M 5.11%
100,000
ATRS
12
DELISTED
Antares Pharma, Inc.
ATRS
$2.18M 4.71%
500,000
TYME
13
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
$1.89M 4.09%
1,500,000
VYNE icon
14
VYNE Therapeutics
VYNE
$19.7M
$1.58M 3.42%
25,000
+2,778
GNLN icon
15
Greenlane Holdings
GNLN
$4.15M
– –
0
MDXG icon
16
MiMedx Group
MDXG
$651M
$1.56M 3.38%
+125,000
ADMS
17
DELISTED
Adamas Pharmaceuticals
ADMS
$528K 1.14%
100,000
GMDA
18
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$481K 1.04%
75,000
+25,000
AUPH icon
19
Aurinia Pharmaceuticals
AUPH
$1.85B
– –
-100,000
SPXU icon
20
ProShares UltraPro Short S&P 500
SPXU
$526M
– –
0
SQQQ icon
21
ProShares UltraPro Short QQQ
SQQQ
$2.6B
– –
0
VIXY icon
22
ProShares VIX Short-Term Futures ETF
VIXY
$83.7M
– –
0
AMRN
23
Amarin Corp
AMRN
$319M
– –
0